Clinical trials: Cancer Disease Progression
Leukemia
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01500499
- Testing
- gene expression analysis, gene rearrangement analysis, polymerase chain reaction
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Neuroendocrine Tumor, Carcinoid
RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide
Neuroendocrine tumors are derived from the neuroendocrine system of the gastroenteropancreatic and bronchopulmonary tract systems.
- Conditions
- Neuroendocrine Tumor, Carcinoid, Neuroendocrine Carcinoma
- Trial name
- RegisterNET (NCT02270567)
- Testing
- NETest
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Wren Laboratories LLC
Gastrointestinal Cancer
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
This is a Phase I study to evaluate the safety and tolerability of sacituzumab govitecan in combination with capecitabine for advanced gastrointestinal cancers after progression on standard therapy, and to assess correlation of…
- Trial name
- NCT06065371
- Testing
- Capecitabine, Sacituzumab govetican
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Henry Ford Health System
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
This phase II trial tests the effect of RP2 and tivozanib in treating patients with renal cell cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that is growing…
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- NCT07218692
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 2 sites in United States
- Sponsor
- City of Hope Medical Center
Disorder Related to Bone Marrow Transplantation, Leukemia
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if combining busulfan with clofarabine and fludarabine can help control the disease better than the previous standard method (using busulfan and fludarabine alone) in patients…
- Conditions
- Disorder Related to Bone Marrow Transplantation, Leukemia, Transplantation Infection
- Trial name
- NCT01471444
- Testing
- Fludarabine, Clofarabine, Busulfan
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
This is a phase III clinical trial to evaluate the efficacy and safety of BPI-16350 in combination with Fulvestrant versus placebo combined with Fulvesrant in Patients who have HR positive and HER2 negative locally…
- Trial name
- NCT05433480
- Testing
- BPI-16350, Fulvestrant
- Where
- 64 sites in China
- Volunteers
- 274 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following…
- Trial name
- COMPEL (NCT04765059)
- Testing
- Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
- Where
- 40 sites in United States, China and 4 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
Melanoma
Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.
Patients with locally advanced melanoma are at high risk for recurrence following surgical treatment. More patients with stage IV melanoma remain in complete remission following systemic therapy.
- Trial name
- DW-MRi (NCT02907827)
- Testing
- follow up DW MRI
- Where
- 2 sites in Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Lung Cancer Stage IV
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
About 20%-40% of NSCLC patients develop intracranial metastases, and most clinical studies suggest that the survival of lung cancer patients will be significantly shortened once they develop intracranial metastases.
- Trial name
- NCT04519983
- Testing
- Aumolertinib Oral Tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Cancer Hospital, China
Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy
Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer
It is still a challenge for urologic surgeon to prevent the post transurethral resection of bladder tumor (TURBT) recurrence of moderate-high risk non-muscle invasive bladder tumor.
- Conditions
- Bladder Cancer, Gemcitabine and Cisplatin Chemotherapy, Epirubicin Instillation, Recurrence
- Trial name
- NCT02716961
- Testing
- Gemcitabine, cisplatin
- Where
- China
- Volunteers
- 208 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer, HER2-low Breast Cancer
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab…
- Conditions
- Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
- Trial name
- TRADE DXd (NCT06533826)
- Testing
- Trastuzumab Deruxtecan, Datopotamab Deruxtecan
- Where
- 11 sites in United States
- Volunteers
- 357 people
- Sponsor
- Ana C Garrido-Castro, MD
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This phase II trial is studying how well giving erlotinib together with sorafenib works in treating patients with progressive or recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00445588
- Testing
- erlotinib hydrochloride, sorafenib tosylate, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma in Relapse, Multiple Myeloma Progression
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
The intended study is designed as a a phase IV pragmatic multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II, Multiple Myeloma Stage I
- Trial name
- RithMM (NCT03428373)
- Testing
- Rivaroxaban, ASA
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
The purpose of this study is to evaluate the safety and efficacy of the combination therapy with Transcatheter Arterial Chemoembolization (TACE) and sorafenib compared to TACE alone in patients with unresectable hepatocellular…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
- Trial name
- TACTICS (NCT01217034)
- Testing
- TACE with sorafenib, TACE alone
- Where
- Japan
- Volunteers
- 228 people
- Sponsor
- Kindai University
Breast Cancer, HER2-positive Breast Cancer
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
In 2020, the incidence of breast cancer surpassed that of lung cancer for the first time, becoming the number one cancer in the world. HER2 is an important prognostic indicator and therapeutic target for breast cancer.
- Trial name
- NCT05474690
- Testing
- Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
- Where
- China
- Sponsor
- Henan Cancer Hospital
Breast Cancer, HER2-positive Breast Cancer
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before…
- Trial name
- NCT06276868
- Testing
- Dalcilib+letrozole+HP treatment group
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Henan Cancer Hospital
Anal AIN3, Anal Carcinoma
Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients
Evaluation of the 3-years anal carcinoma (AC) incidence in patient with anal AIN3 lesions, and factors associated with this AC. A retrospective cohort study will be conducted (2000-2013) followed by a prospective cohort study…
- Trial name
- AIN3 (NCT01877135)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- French Society of Coloproctology
Brain Tumor
Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?
PET-MRI scanning regarding amino acid metabolic profile, functional and morphological details will be performed on set intervals to patients with brain tumor \& brain metastases in order to try to optimize the study protocol…
- Trial name
- NCT03068520
- Testing
- PET MR
- Where
- Israel
- Volunteers
- 140 people
- Sponsor
- Assuta Medical Center
Cannabis Use, Cachexia; Cancer
Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia
A large number of patients with advanced cancer also suffer from cachexia. Cachexia is a syndrome characterized by loss of skeletal muscle mass (with/or without loss of fat mass) that cannot be reversed by nutritional support and…
- Conditions
- Cannabis Use, Cachexia; Cancer, Advanced Cancer
- Trial name
- SERENITY (NCT04001010)
- Testing
- PPP011
- Where
- Canada
- Volunteers
- 334 people
- Sponsor
- Tetra Bio-Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.